Microbot Medical (NASDAQ:MBOT) PT Lowered to $7.00 at HC Wainwright

Microbot Medical (NASDAQ:MBOT) had its target price cut by stock analysts at HC Wainwright from $8.00 to $7.00 in a report released on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock.

Microbot Medical Stock Performance

MBOT stock opened at $1.03 on Tuesday. The company has a market capitalization of $14.83 million, a PE ratio of -0.95 and a beta of 1.64. Microbot Medical has a 52 week low of $1.00 and a 52 week high of $4.37. The company’s 50-day simple moving average is $1.22 and its 200 day simple moving average is $1.29.

Institutional Investors Weigh In On Microbot Medical

A number of large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its stake in Microbot Medical by 4.1% during the third quarter. Dimensional Fund Advisors LP now owns 92,451 shares of the biotechnology company’s stock worth $442,000 after buying an additional 3,609 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Microbot Medical by 28.0% in the second quarter. Renaissance Technologies LLC now owns 20,095 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 4,400 shares during the last quarter. Cetera Advisor Networks LLC bought a new position in Microbot Medical in the 1st quarter valued at approximately $78,000. Wells Fargo & Company MN raised its holdings in Microbot Medical by 6,713.4% in the 2nd quarter. Wells Fargo & Company MN now owns 12,741 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 12,554 shares during the last quarter. Finally, Virtu Financial LLC raised its holdings in Microbot Medical by 75.9% in the 4th quarter. Virtu Financial LLC now owns 42,046 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 18,138 shares during the last quarter. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Company Profile

Microbot Medical Inc operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.